HighTower Advisors LLC Boosts Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

HighTower Advisors LLC lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 89.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,666 shares of the company’s stock after acquiring an additional 14,958 shares during the quarter. HighTower Advisors LLC owned 0.06% of Prestige Consumer Healthcare worth $2,473,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of PBH. JPMorgan Chase & Co. increased its holdings in Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after buying an additional 8,533 shares during the last quarter. Geode Capital Management LLC increased its holdings in Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after buying an additional 50,961 shares during the last quarter. Avior Wealth Management LLC increased its holdings in Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock valued at $668,000 after buying an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Prestige Consumer Healthcare by 5.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after buying an additional 33,844 shares during the last quarter. Finally, Barclays PLC increased its holdings in Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after buying an additional 71,730 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $84.12 on Friday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The company has a market capitalization of $4.17 billion, a price-to-earnings ratio of 19.70, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The firm has a 50-day simple moving average of $82.46 and a 200-day simple moving average of $78.62. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

PBH has been the topic of several research reports. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Tuesday, March 18th. Canaccord Genuity Group raised their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada raised their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and an average price target of $93.33.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.